Seçkin Akçay

Seçkin Akçay

Auto-generated profile, based on publicly available information

Seçkin Akçay

Division of Endocrinology and Metabolic Diseases, Department of Internal Medicine, Faculty of Medicine, Marmara University, İstanbul, Turkiye

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2020 in Turkish Journal of Hematology
Verified
Journal Article
Open access
FAFatma Arikan
Fatma Arikan
YYYasin Yıldız
Yasin Yıldız
TETarık Ercan
Tarık Ercan
ÖOÖzen Oruç
Özen Oruç
SASeçkin Akçay
Seçkin Akçay
TTTülin Tuğlular
Tülin Tuğlular


12 December 2025 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
ACAsena GÖKÇAY CANPOLAT
Asena GÖKÇAY CANPOLAT
KAKemal Ağbaht
Kemal Ağbaht
AEAtilla Halil Elhan
Atilla Halil Elhan
MCMustafa Cesur
Mustafa Cesur
ZUZiynet Alphan Uc
Ziynet Alphan Uc
MSMustafa - Sahin
Mustafa - Sahin
Background/aim: To describe Graves’ Disease (GD) associated with COVID-19 infection (COVID) or its vaccines (VAC) and to compare the clinical presentations, laboratory parameters, and short-term clinical course of the disease among different etiology groups (COVID, VAC, and GD control). Materials and methods: Included in this multicenter matched case–control, retrospective cohort study were 239 patients with newly diagnosed (n = 196) or recurrent GD (n = 43) associated with COVID (n = 79) or VAC (n = 160). Each case was matched (1:1) with a control who had been diagnosed with GD prior to COVID. Results: The median age of the entire group was 42 years (female:male = 137:102). Both the COVID (4.6-fold) and VAC (4.1-fold) groups demonstrated higher TSH receptor antibody (TRAb) titers (p < 0.001) compared with the control group (3.5-fold), as well as a higher proportion of recurrent cases. At baseline, the COVID group had higher free triiodothyronine (fT3) levels than the other groups. Graves orbitopathy (GO) was observed in 60 patients (12.6%), with a higher frequency in classical GD (18.4%). At baseline, the variables associated with thyrotoxicosis severity (defined as fT3 levels) were younger age, higher thyroid gland volume (TGV), and etiology, with the COVID and, to a lesser extent, VAC groups presenting with higher fT3 levels. The variables associated with GO were higher TGV, TRAb titers, and smoking, while no association with etiology was identified. Conclusion: The clinical course was similar in all groups other than in some laboratory findings. Although the frequency of GO associated with COVID and VAC was lower, the proportion of cases with a Clinical Activity Score of ≥3 was higher compared to GD. This pattern suggests a potentially stronger immunologic trigger in these cases.

17 July 2024 in Kidney and Blood Pressure Research
Verified
Journal Article
Open access
PDF file
SASeckin Akcay
Seckin Akcay
ZKZarife Nigar Özdemir Kumral
Zarife Nigar Özdemir Kumral
OCOzlem Tugce Cilingir-Kaya
Ozlem Tugce Cilingir-Kaya
IEIrem Peker Eyuboglu
Irem Peker Eyuboglu
MAMustafa Akkiprik
Mustafa Akkiprik
MKMehmet Koc
Mehmet Koc
Introduction: Contrast nephropathy (CN) is characterized by oxidative stress, vasoconstriction, tubular toxicity and hypoxia of the renal medulla. We aimed to test the therapeutic effects of an α7 nicotinic acetylcholine receptor (nAChR) agonist, GTS-21, in an experimental CN model. Methods: Male Sprague‒Dawley rats (n=40) were divided into 4 groups: saline-treated control, GTS-21-treated control, contrast, and GTS-21-treated contrast groups. Starting on the 1st day, GTS-21 (4 mg/kg, intraperitoneally) or saline was administered twice a day for 3 days. CN was induced on the second day by intravenous injection of indomethacin (10 mg/kg), L-NAME (10 mg/kg), and a contrast agent with high osmolarity (6 ml/kg; Urografin 76%). At the 72nd hour, blood and kidney samples were obtained for the determination of biochemical, histological, and gene expression parameters. Results: Compared to those in control rats, the elevated serum BUN level in the contrast group decreased with GTS-21 treatment, while H&E staining and TUNEL assays showed that contrast-induced renal injury was improved by GTS-21. Moreover, GTS-21 treatment in the CN also increased the antioxidant glutathione level. In the contrast group, a significant increase in IL-6 expression and a decrease in TGF-β expression were observed; however, GTS-21 treatment decreased IL-6 expression and increased TGF-β expression. Conclusion: GTS-21 significantly alleviated renal injury parameters through antioxidant, anti-inflammatory, and antiapoptotic mechanisms in the CN model.